DeNIS collaboration: setting the future research agenda
نویسندگان
چکیده
منابع مشابه
Prolonged grief: setting the research agenda
BACKGROUND Prolonged grief disorder is proposed for the International Classification of Diseases (ICD-11), though it was rejected as a diagnosis for DSM-5. OBJECTIVE This review outlines findings and defines important areas for future research viewed from a lifespan perspective. RESULTS The development and psychometric evaluation of measures for the new diagnosis is paramount, specifically ...
متن کاملMenthol cigarettes: setting the research agenda.
The First Conference on Menthol Cigarettes was convened in Atlanta, Georgia, on March 21–22, 2002. The purpose of the conference was to evaluate the present state of the science concerning the potential increased harm caused by adding menthol to cigarettes, and to set the priorities for further studies of menthol cigarettes. More than 80 researchers and tobacco control experts participated in t...
متن کاملTrauma and PTSD: setting the research agenda
U p to 80% of people encounter severe adverse events in their lives (De Vries & Olff, 2009). Most people will be resilient or quickly recover from negative symptoms, but a significant proportion will develop posttraumatic stress disorder (PTSD) leading to a lifetime prevalence of PTSD in about 7% (De Vries & Olff, 2009; Kessler et al., 2005). These events precipitate not only PTSD but also majo...
متن کاملMachines as Teammates: A Collaboration Research Agenda
Humans will soon need to adapt to a collaborative setting in which technology becomes a smart collaboration partner that works with a group to achieve its goals. It is therefore time for collaboration researchers to explore the vast opportunities afforded by smart technology and to test its utility for enhancing team processes and outcomes. In this paper, we take a long view on the implications...
متن کاملSetting the research agenda for future clinical trials on the use of biologics in rheumatology.
The introduction of anti-TNF drugs for RA has transformed the outlook for patients and they are now an accepted part of clinical practice [1]. Their use has spread to several other related inflammatory disorders. There are five anti-TNF agents licensed for use in RA in Europe, with even more to come, and several other biologic agents for RA are also available including abatacept, rituximab and ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Lancet Global Health
سال: 2017
ISSN: 2214-109X
DOI: 10.1016/s2214-109x(16)30286-8